-
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth investment with 2023 CAPEX at 25% of sales Solid free cash flow at CHF 329 million Proposed 14% dividend increase from CHF 3.50 to CHF 4.00 per share Return of excess capital continues with ongoing share buyback up to CHF 2 billion Outlook 2024: flat CER sales growth and CORE EBITDA margin in the high twenties Mid-Term Guidance 2024 – 2028 confirmed Basel, Switzerland, 26 January 2024 – Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting…
-
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023. The bonds have a maturity of 4.5 years and 7.5 years respectively with coupons of 2.250% and 2.600%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for refinancing and general corporate purposes. Key Data Issue Size 4.5-Year Bond: CHF 185 million Expected Payment Date: 16 November 2023…
-
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023: higher end of mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin Business growth in 2024 will be offset by one-off events, with an anticipated margin in the high twenties Dividend pay-out commitment range increased to 35 to 45% At its Capital Markets Day in Visp (CH), Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028. The following five strategic priorities support the company’s ongoing commitment to sustainable value creation:…
-
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
. New agreement to establish global commercial manufacturing capacity for Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in adult and pediatric populations Expanded collaboration builds on Vaxcyte’s current strategy to conduct initial commercial launch of VAX-24 in adults from existing Lonza facilities in Visp (CH) Long-standing relationship between the companies further enhanced as Vaxcyte progresses lead vaccine candidate into late-stage clinica development New purpose-built large-scale manufacturing suite in Lonza’s Ibex® Dedicate Biopark Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, and Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the companies have entered into…
-
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of filling capacity will enhance Lonza’s end-to-end integrated offering for manufacturing antibody-drug conjugates (ADCs) drug substance and drug product Approximately 115 new jobs anticipated at Lonza Stein (CH), with operations starting in 2027 Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the extension of a collaboration with a major biopharmaceutical partner for the commercial-scale filling of ADCs. Under the terms of the agreement, Lonza will construct a dedicated commercial-scale aseptic cGMP filling line at its Stein (CH) site. The new dedicated filling line…
-
Lonza Further Extends Collaboration with Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation Two new purpose-built large-scale bioconjugation suites in Lonza’s Ibex® Dedicate Biopark to generate around 180 new jobs, with operations expected to begin in 2026 Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today an extension of a long-term collaboration with a major global biopharmaceutical partner. The extended agreement will increase the current dedicated bioconjugation capacity fourfold by adding two new bioconjugation suites for the commercial supply of…
-
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an overview of Lonza’s offerings, capabilities, markets and sources of competitive advantage Lonza reconfirms Outlook 2023 at mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin Lonza today announced its plans for the company’s Capital Markets Day, which is scheduled to take place on 17th October 2023. There will be updates provided by each of Lonza’s four Divisional Presidents, including the following topics: the markets in which each division operates, main offerings and capabilities, sources of competitive advantage, and current growth projects. The Chief Financial Officer will also provide…
-
Board Announcement
CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17 confirmed Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed. The medium-term strategy and outlook will be discussed in detail at the Capital Markets Day in Visp on 17th October 2023. Christoph Maeder, Lead Independent Director and Vice-Chairman, Lonza, said: “Albert has agreed to lead the Company as CEO…
-
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a margin of 30% Good momentum in commercial CDMO business Group Outlook 2023 update: mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin, reflecting slower growth than expected in early-stage services and continued weak demand in the nutraceutical capsules market driving underutilization Mid-Term Sales Guidance confirmed with updated margin range at 31 to 33% Lonza has reported sales of CHF 3.1 billion and sales growth of 3.2% AER3 (5.6%1 CER), corresponding to around 10% CER underlying sales growth. CHF 922 million…
-
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies for cytotoxic ADCs, targeted gene therapy, immune cell engagers applications and beyond The acquisition comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets,…